Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746366 · ClinicalTrials.gov registry record · Early Phase 1
[C-11]PiB PET Imaging in Alcohol Use Disorders
A Early Phase 1 study of Alcohol Use Disorder, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT03746366 is a Early Phase 1 study of Alcohol Use Disorder that has completed, run by University of Pittsburgh. The registered enrollment target is 39 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03746366, a Early Phase 1 study of Alcohol Use Disorder, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether alcoholics (AUD) have a greater rate of amyloid positivity (ABeta+) compared to an age-matched cognitively normal control group (HC).
Conditions Studied
Interventions
- RADIATION [C-11]
- DRUG Pittsburgh Compound B
Study Locations (1)
Pennsylvania
- University of Pittsbyurgh PET Facility - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2020-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746366
The ClinicalTrials.gov registry entry for NCT03746366 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (88% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which [C-11] is the first listed.
NCT03746366 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03746366 about?
NCT03746366 is a clinical study titled "[C-11]PiB PET Imaging in Alcohol Use Disorders". To determine whether alcoholics (AUD) have a greater rate of amyloid positivity (ABeta+) compared to an age-matched cognitively normal control group (HC).
What is the current status of trial NCT03746366?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2018-12-01. Estimated completion is 2020-07-01.
What conditions does trial NCT03746366 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT03746366?
The interventions under investigation include: [C-11] (RADIATION), Pittsburgh Compound B (DRUG).
Who is sponsoring clinical trial NCT03746366?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03746366 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impulsivity Domains and Subjective Response
RECRUITING · Early Phase 1
-
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
RECRUITING · Early Phase 1
-
Suvorexant and Alcohol
RECRUITING · Early Phase 1
-
Anxiety During Abstinence in AUD
RECRUITING · Early Phase 1
-
Diclofenac as a KMO Inhibitor
ACTIVE NOT RECRUITING · Early Phase 1
-
Behavioral Alcohol Responses (BAR) Study
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.